Navigation Links
Understanding and Treating Congenital Diaphragmatic Hernia

use by pediatric surgeons and pathologists at several institutions. We anticipate that widespread use of a standard approach to CDH classification will improve the quality of information in the medical literature, and ultimately will be used to develop genotype-phenotype correlations, they state.

In the womb, fetal lung growth and maturation are strongly affected by the extent to which developing lungs are stretched by liquid that fills future airspaces. In the article by Paul A. Khan, Marc Cloutier, and Bruno Piedboeuf of the Centre de Recherche du Centre hospitalier de LUniversite Laval data are presented from examination of sheep, rabbit, rat and mice models of tracheal occlusion (TO). TO, a surgery that is performed in utero helps stimulate fetal lung growth and remedy pulmonary hypoplasia by closing the trachea, thus preventing fluid from leaving the lungs and causing them to be stretched. TO not only promotes development of an increased gas exchange surface area, but also markedly remodels pulmonary vasculature and stimulates endothelial cell proliferation, the authors state. In all of the models they note that TO eliminates the thickening of fine blood vessels that afflicts CDH patients. With future technical refinement and improved post-surgical care, TO may well become a more reliable and effective means of clinical intervention, they conclude.

Advances in understanding diaphragm development from the evaluation of genetic mouse models were discussed in an article by Ackerman and John J. Greer of the University of Alberta. They note that there are genes that are now known to play a role in diaphragm development, and that many of these genes are also important for cardiac and lung development. They describe the role of the transcription factor Fog2: Fog2 is the first gene recognized to be necessary for both primary lung development and primary diaphragm development providing evidence for the hypothesis that diaphragmatic defec
'"/>




Page: 1 2 3 4

Related medicine news :

1. Understanding The Predictors Of Prostate Cancer
2. Understanding Restless Legs Syndrome
3. Understanding Lung Cancer Metastasis
4. Understanding The Link Between Hormone Replacement and Respiratory Disease
5. Understanding The Risks Of Hormone Therapy
6. Understanding The Link Between Metabolic Syndrome And Drinking Patterns
7. A Better Understanding Of The Brain Network
8. Understanding The Predictor’s Of Alzheimer’s Diseae
9. Understanding The Harmful Effects Of Radiation Exposure
10. Understanding The Origin Of Tumors
11. Understanding Insulin Resistance
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...who are overweight or obese have a greater risk of...sease, a new study by US and Australian researcher...s Jefferson University in Philadelphia and the Edi...Australia - say that being obese 'almost certainly...
...hers from Germany have discovered a novel, less in...nary veins. This technique, called ECG-gated cardi... associated with very few complications // . It is...ed diagnostic quality and treatment. A comparison...
...n cancer gel developer Peplin has said that it wou...st-action cancer cream since it was able to get an...ors for this purpose. The company based in Quee...05 compound as a treatment for actinic keratosis a...
...ube has been designed by scientists belonging to t...for delivering cells or molecules for treatment, t...ished in the Biomedical Microdevices. In the initi...ned box, but when heat is applied, the sides fold ...
Other Medicine News:Health News:Obesity could lead to Alzheimer's 2Health News:Nanocubes Designed For Delivering Cells 2
(Date:10/6/2008).../- Genaera,Corporation (Nas...hase 1,clinical trial of trodusquemine (MSI-1436),...f type 2 diabetes and obesity. MSI-1436 is a novel...that controls the function,of both the leptin and ...,appetite. In the study, MSI-1436 was found to be ...
(Date:10/6/2008)...te to severe patients achieved endoscopic,response...ssion at Week 10,in data from a 54-week open-label...enterology (ACG) Annual Scientific Meeting, ORLAN...ed data from a,large, prospective study investigat... with a biologic compound. The data presented at t...
(Date:10/6/2008)...eristics of Naltrexone SR Associated with ...PHOENIX, Oct. 6 /- Orexigen...eutical company focused on the treatment of,obesit...rs, today presented,data showing the investigation...), successfully achieved key objectives (lowered n...
(Date:10/6/2008)...rstCall/ -- Dendreon Corporation (Nasdaq:,DNDN) wi..., 2008 at 9:00 AM,ET (6:00 AM PT) to review the ou...otherapy for Prostate AdenoCarcinoma Treatment, al...(sipuleucel-T), the Company,s investigational,acti...anced prostate,cancer., Those interested may a...
Breaking Medicine Technology:Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by 243 6 Billion by 2016 14690 1Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by 243 6 Billion by 2016 14690 2Statement By Robert McSwain Acting Director Indian Health Service Regarding National Native HIV AIDS Awareness Day 2008 14688 1Statement By Robert McSwain Acting Director Indian Health Service Regarding National Native HIV AIDS Awareness Day 2008 14688 2Ex Allergan Vice President Joins Kalologie Skincare Board of Directors 4078 1Ex Allergan Vice President Joins Kalologie Skincare Board of Directors 4078 2Experience a Close Up View of the Beijing 2008 Olympic Games 14685 1Experience a Close Up View of the Beijing 2008 Olympic Games 14685 2Experience a Close Up View of the Beijing 2008 Olympic Games 14685 3
...l 30, 2007 /PRNewswire-FirstCall/,-- , - Femara re...ungs, the brain or the bone which has a worse prog...ast , Newly published data in the May issue of Ann... after two years of post-surgical,therapy, postmen...cancer treated with Femara experienced 30 percent ...
...ation with the Centro de,Investigación M&ea...arra, Pamplona, Spain, is being presented at,Porph...erlands. , AMSTERDAM, the Netherlands, May 1st 200...eader in the field of human gene therapy,will tod...erapy to,treat acute intermittent porphyria (AIP) ...
Other Medicine Technology:Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 2Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 3Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 5Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 2Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 3
...) is the sulfate ester of DHEA, derived from sulfa... in adrenal and extradrenal tissues. DHEA is the m...nd is a precursor for testosterone and estrogen bi...nic activity, which for unsulfated DHEA has been e...
...ompetition principle and the microplate separation...e and a fixed amount of DHEA-S conjugated with hor... of a polyclonal DHEA-S antiserum coated onto the ...te is washed to stop the competition reaction. Hav...
Inquire
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Medicine Products: